Neumora reported a nine-month net loss of $131.0 million and $85.7 million in cash and cash equivalents as of September 30, 2026, raising substantial doubt about its ability to continue as a going concern within one year of filing.
NMRA · Neumora Therapeutics, Inc.
Substantial doubt about the company's ability to continue as a going concern.
“Accordingly, the Company has concluded that substantial doubt exists about its ability to continue as a going concern.”View the 10-Q filed Nov 16, 2026
You came from your AI assistant. Add Equibles to it and ask about this data directly, free.
Price & Indicators
Key stats
- Short volume, last session
- 73%
- Last earnings
- Mar 30, 2026
- Latest filing
- 10-Q · Nov 16
- Price history
- Sep 2023 to Nov 2026
Up next
Latest documents
Neumora Therapeutics submitted an IND for NMRA-215 to the U.S. Food and Drug Administration, reported $85.7 million cash as of September 30, 2026 and a third-quarter net loss of $34.4 million, and is not providing updated financial runway guidance.
Neumora received written notice from Nasdaq on October 26, 2026 that its common stock is below the $1.00 minimum bid price for continued listing. It has until April 26, 2027 to regain compliance, which requires a closing bid of at least $1.00 for ten consecutive business days.
Metrics snapshot
Useful current figures from the complete screener profile.
Equibles Research
our published analysis of this companyEquibles Rating
blended score · not investment adviceBlended from price, momentum, positioning, fundamentals & volatility · daily-close · not investment advice. Market backdrop is context, not part of the score.
Technicals
trend & momentum for long-term holders Strong SellIllustrative technical + ownership context — a signal mix, not investment advice.
Key metrics
Earlier KPI extraction records exist, but do not meet the current evidence-completeness requirements. No current verified series is available. Earlier figures remain withheld until revalidated; this is not evidence that the company reports no KPIs.
Versus peers
Biotechnology — same industry group| Company | Mkt cap | YTD | Rev growth Y/Y | P/E | Short % shares |
|---|---|---|---|---|---|
|
NMRA
this stock
Neumora Therapeutics, Inc.
|
$63.01M | -81.3% | — | — | 3.7% |
|
VRTX
Vertex Pharmaceuticals Inc
|
$130.58B | +13.6% | +46.2% | 33.2 | 1.9% |
|
REGN
Regeneron Pharmaceuticals, Inc.
|
$95.24B | +19.3% | +20.8% | 20.4 | 2.1% |
|
MRNA
Moderna, Inc.
|
$78.90B | +561.2% | +4.3% | — | 8.2% |
|
CSLLY
Csl Ltd
|
$62.17B | — | — | — | 0.0% |
Peers by industry group · P/E from as-reported trailing EPS · short % is of shares outstanding
At a glance
key data from every section- Filed
- Nov 16, 2026
- This year
- 21
Neumora reported a nine-month net loss of $131.0 million and $85.7 million in cash and cash equivalents as of September 30, 2026, raising substantial doubt about its ability to continue as a going concern within one year of filing.
ViewPerformance
| 5D | 20D | 120D | MTD | YTD | |
|---|---|---|---|---|---|
| NMRA | -22.2% | -12.0% | -80.9% | -9.1% | -81.4% |
| SPY | -8.6% | -9.2% | -9.2% | -8.7% | +1.2% |
| vs SPY | -13.6% | -2.8% | -71.7% | -0.4% | -82.5% |